Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change

Mydecine (OTC: MYCOF) and Lobe Sciences (OTCQB: LOBEF), two companies in the psychedelics space, have filed patent applications. This is the first step in the process of receiving a patent, which needs to be granted by an overseeing body.

Mydecine's Patent On The MYCO-006 Family Of Compounds

Mydecine is a company developing innovative first- and-second-generation therapeutics for the treatment of PTSD, depression, anxiety, addiction and other mental health disorders. It has filed a new, full patent application covering the MYCO-006 family of novel short-acting MDMA analogs with the World Intellectual Property Organization.

The provisional patent application was done in July 2021. The family of MDMA-like compounds is intended to reduce harm and improve safety compared to MDMA, targeting a reduced duration with the same effects as traditional MDMA.

As Mydecine’s chief scientific officer Rob Roscow expressed: “From Rick Ingrasc's early work in the early 70’s …

Full story available on Benzinga.com

Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change on Benzinga